KaliVir Immunotherapeutics
PA - PittsburghBiotechnology
Focus: KaliVir is an early-stage oncology biotech focused on oncolytic vaccinia virus immunotherapies for solid tumors. Founded in 2023 and based in Pittsburgh, the company is pre-revenue with a single Phase 1 program.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About KaliVir Immunotherapeutics
AI assessmentNot HiringNo open roles listed right now. Follow KaliVir Immunotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
VET3-TGI
Solid Tumor, AdultClinical Trials (1)
NCT06444815A Study of VET3-TGI in Patients With Solid Tumors
Phase 1Help build intelligence for KaliVir Immunotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.